Benjamin W Teh1, Simon J Harrison2, Leon J Worth3, Karin A Thursky3, Monica A Slavin4. 1. Department of Infectious Diseases, Peter MacCallum Cancer Centre, East Melbourne, Australia; Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia. Electronic address: ben.teh@petermac.org. 2. Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia; Department of Haematology, Peter MacCallum Cancer Centre, East Melbourne, Australia. 3. Department of Infectious Diseases, Peter MacCallum Cancer Centre, East Melbourne, Australia; Department of Medicine, University of Melbourne, Parkville, Australia. 4. Department of Infectious Diseases, Peter MacCallum Cancer Centre, East Melbourne, Australia; Department of Medicine, University of Melbourne, Parkville, Australia; Victorian Infectious Diseases Service, Doherty Institute for Infection and Immunity, Australia.
Abstract
BACKGROUND: The objective of this review was to determine the impact of immunomodulatory drugs (IMiDs) and proteasome inhibitor (PI)-based therapy on infection risk in patients with myeloma across three treatment periods: induction, maintenance therapy and relapse/refractory disease (RRMM). METHODS: A systematic review and meta-analysis of randomised controlled trials (RCT) of IMiD and PI-based therapy versus conventional therapy from 1990 to 2015 using MEDLINE, EMBASE and CENTRAL was conducted. Study methods, characteristics, interventions, outcomes and rate of infection were extracted using a standardised tool. FINDINGS: Thirty RCTs of 13,105 patients fulfilled inclusion criteria. The rate of severe infection with the use of IMiD-based therapy was 13.4%, 22.4%, 10.5% and 16.6% for induction therapy for non-transplant- and transplant-eligible patients, maintenance therapy and therapy for RRMM, respectively. Rate of severe infection with PI-based induction in transplant-eligible patients was 19.7%. Compared to conventional therapy, use of IMiD-based induction therapy was associated with reduced risk for transplant patients (RR 0.76, p < 0.01). There was no significant difference with PI-based therapy. For maintenance therapy and RRMM, use of IMiD-based therapy was significantly associated with 74% and 51% increased risk of severe infection, respectively. Compared to thalidomide, bortezomib-based induction therapy and lenalidomide maintenance therapy were associated with increased risk of severe infection (RR 2.03, p < 0.01; RR 1.95, p = 0.03). INTERPRETATION: The differential impact of myeloma therapies on risk for infection and the effect of treatment phases upon risk have now been established. Thalidomide is associated with the lowest risk of severe infection when used for induction and maintenance therapy. FUNDING: Fight Cancer Foundation.
BACKGROUND: The objective of this review was to determine the impact of immunomodulatory drugs (IMiDs) and proteasome inhibitor (PI)-based therapy on infection risk in patients with myeloma across three treatment periods: induction, maintenance therapy and relapse/refractory disease (RRMM). METHODS: A systematic review and meta-analysis of randomised controlled trials (RCT) of IMiD and PI-based therapy versus conventional therapy from 1990 to 2015 using MEDLINE, EMBASE and CENTRAL was conducted. Study methods, characteristics, interventions, outcomes and rate of infection were extracted using a standardised tool. FINDINGS: Thirty RCTs of 13,105 patients fulfilled inclusion criteria. The rate of severe infection with the use of IMiD-based therapy was 13.4%, 22.4%, 10.5% and 16.6% for induction therapy for non-transplant- and transplant-eligible patients, maintenance therapy and therapy for RRMM, respectively. Rate of severe infection with PI-based induction in transplant-eligible patients was 19.7%. Compared to conventional therapy, use of IMiD-based induction therapy was associated with reduced risk for transplant patients (RR 0.76, p < 0.01). There was no significant difference with PI-based therapy. For maintenance therapy and RRMM, use of IMiD-based therapy was significantly associated with 74% and 51% increased risk of severe infection, respectively. Compared to thalidomide, bortezomib-based induction therapy and lenalidomide maintenance therapy were associated with increased risk of severe infection (RR 2.03, p < 0.01; RR 1.95, p = 0.03). INTERPRETATION: The differential impact of myeloma therapies on risk for infection and the effect of treatment phases upon risk have now been established. Thalidomide is associated with the lowest risk of severe infection when used for induction and maintenance therapy. FUNDING: Fight Cancer Foundation.
Authors: J-S Claveau; R LeBlanc; I Ahmad; J Ferreira; A-A Pistono; N Bambace; L Bernard; S Cohen; J-S Delisle; T Kiss; S Lachance; J Roy Journal: Bone Marrow Transplant Date: 2017-07-10 Impact factor: 5.483
Authors: Cristina Encinas; José-Ángel Hernandez-Rivas; Albert Oriol; Laura Rosiñol; María-Jesús Blanchard; José-María Bellón; Ramón García-Sanz; Javier de la Rubia; Ana López de la Guía; Ana Jímenez-Ubieto; Isidro Jarque; Belén Iñigo; Victoria Dourdil; Felipe de Arriba; Clara Cuéllar Pérez-Ávila; Yolanda Gonzalez; Miguel-Teodoro Hernández; Joan Bargay; Miguel Granell; Paula Rodríguez-Otero; Maialen Silvent; Carmen Cabrera; Rafael Rios; Adrián Alegre; Mercedes Gironella; Marta-Sonia Gonzalez; Anna Sureda; Antonia Sampol; Enrique M Ocio; Isabel Krsnik; Antonio García; Aránzazu García-Mateo; Joan-Alfons Soler; Jesús Martín; José-María Arguiñano; María-Victoria Mateos; Joan Bladé; Jesús F San-Miguel; Juan-José Lahuerta; Joaquín Martínez-López Journal: Blood Cancer J Date: 2022-04-19 Impact factor: 9.812
Authors: Charles Dumontet; Cyrille Hulin; Meletios A Dimopoulos; Andrew Belch; Angela Dispenzieri; Heinz Ludwig; Philippe Rodon; Jan Van Droogenbroeck; Lugui Qiu; Michele Cavo; Ann Van de Velde; Juan José Lahuerta; Olivier Allangba; Jae Hoon Lee; Eileen Boyle; Aurore Perrot; Philippe Moreau; Salomon Manier; Michel Attal; Murielle Roussel; Mohamad Mohty; Jean Yves Mary; Alexandre Civet; Bruno Costa; Antoine Tinel; Yann Gaston-Mathé; Thierry Facon Journal: Leukemia Date: 2018-04-26 Impact factor: 11.528
Authors: Hareth Nahi; Michael Chrobok; Charlotte Gran; Johan Lund; Astrid Gruber; Gösta Gahrton; Per Ljungman; Arnika Kathleen Wagner; Evren Alici Journal: PLoS One Date: 2019-02-13 Impact factor: 3.240
Authors: Larissa Henze; Christoph Buhl; Michael Sandherr; Oliver A Cornely; Werner J Heinz; Yascha Khodamoradi; Til Ramon Kiderlen; Philipp Koehler; Alrun Seidler; Rosanne Sprute; Martin Schmidt-Hieber; Marie von Lilienfeld-Toal Journal: Ann Hematol Date: 2022-01-07 Impact factor: 3.673
Authors: Benjamin W Teh; Simon J Harrison; Cody Charles Allison; Monica A Slavin; Tim Spelman; Leon J Worth; Karin A Thursky; David Ritchie; Marc Pellegrini Journal: Front Immunol Date: 2017-10-05 Impact factor: 7.561